Cargando…
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
Oncolytic viruses (OVs) are opening new possibilities in cancer therapy with their unique mechanism of selective replication within tumor cells and triggering of antitumor immune responses. HF10 is an oncolytic herpes simplex virus-1 with a unique genomic structure that has non-engineered deletions...
Autores principales: | Eissa, Ibrahim Ragab, Naoe, Yoshinori, Bustos-Villalobos, Itzel, Ichinose, Toru, Tanaka, Maki, Zhiwen, Wu, Mukoyama, Nobuaki, Morimoto, Taishi, Miyajima, Noriyuki, Hitoki, Hasegawa, Sumigama, Seiji, Aleksic, Branko, Kodera, Yasuhiro, Kasuya, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509757/ https://www.ncbi.nlm.nih.gov/pubmed/28770166 http://dx.doi.org/10.3389/fonc.2017.00149 |
Ejemplares similares
-
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
por: Eissa, Ibrahim Ragab, et al.
Publicado: (2018) -
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
por: Wu, Zhiwen, et al.
Publicado: (2019) -
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
por: Abdelmoneim, Mohamed, et al.
Publicado: (2022) -
C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells
por: Morimoto, Daishi, et al.
Publicado: (2021) -
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model
por: Miyajima, Noriyuki, et al.
Publicado: (2021)